MCID: OVR012
MIFTS: 46

Ovarian Serous Cystadenocarcinoma malady

Cancer diseases category

Summaries for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
34MalaCards
See all sources

Fully expand this MalaCard

Download this MalaCard
MalaCards: Ovarian Serous Cystadenocarcinoma is related to cystadenocarcinoma and endometriosis. An important gene associated with Ovarian Serous Cystadenocarcinoma is BIRC5 (baculoviral IAP repeat containing 5), and among its related pathways are TP53 network and Vinka Alkaloid Pathway, Pharmacokinetics. The compounds idoxifene and estradiol benzoate have been mentioned in the context of this disorder. Affiliated tissues include breast and ovary, and related mouse phenotypes are hearing/vestibular/ear and adipose tissue.

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
9Disease Ontology, 11DISEASES, 46Novoseek, 63UMLS, 41NCIt
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer diseases


Aliases & Descriptions:

ovarian serous cystadenocarcinoma 9 11 46 63


External Ids:

Disease Ontology9 DOID:5746
NCIt41 C7978

Related Diseases for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
18GeneCards, 19GeneDecks
See all sources

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 86)
idRelated DiseaseScoreTop Affiliating Genes
1cystadenocarcinoma31.5MUC16
2endometriosis30.3MUC16, ESR1, CYP19A1, VEGFA, ESR2, PGR
3leukemia30.2BAX, BIRC5, ESR2, FAS, AKT1, BCL2
4ovarian cancer30.0BAX, PGR, BCL2, VEGFA, ESR2, FAS
5serous cystadenocarcinoma10.9
6ovarian endometriosis10.3
7plasma cell leukemia10.3
8adenofibroma10.1MUC16
9pericardial effusion10.1MUC16
10cerebral meningioma10.1PGR
11ovarian disease10.1MUC16, CYP19A1
12ovarian cyst10.1ESR2, MUC16, CYP19A1
13estrogen excess10.1CYP19A1, PGR
14malignant pleural mesothelioma10.1MUC16, BIRC5
15sertoli cell tumor10.0CYP19A1, PGR
16endocrine gland cancer10.0CYP19A1, ESR1
17ovarian hyperstimulation syndrome10.0CYP19A1, VEGFA
18benign meningioma10.0BIRC5, PGR
19progesterone resistance10.0PGR, ESR1
20uterine sarcoma10.0CYP19A1, ESR1
21cutaneous t cell lymphoma10.0BAX, FAS, BIRC5
22meningioma10.0PGR, ESR1
23cribriform carcinoma10.0PGR, ESR1
24mammary paget's disease10.0ESR1, PGR
25malignant mixed mullerian tumor10.0ESR1, PGR
26bilateral breast cancer10.0ESR1, PGR
27male breast cancer10.0PGR, ESR1
28li-fraumeni syndrome10.0PGR, ESR1
29leiomyomatosis10.0ESR1, PGR
30adenosarcoma10.0PGR, ESR1
31abrikosov's tumor10.0CYP19A1, MUC16, ESR1
32uterine fibroid10.0ESR1, PGR
33inflammatory breast carcinoma10.0PGR, ESR1
34glioblastoma multiforme10.0VEGFA, BIRC5, BAX
35lymphangioleiomyomatosis10.0PGR, ESR1
36osteoporosis, postmenopausal10.0ESR2, ESR1, CYP19A1
37cervical adenocarcinoma10.0ESR1, PGR, MUC16
38congenital heart disease10.0BAX, AKT1, VEGFA
39angiomyolipoma10.0PGR, ESR1
40papillary carcinoma10.0PGR, ESR1, MUC16
41osteoporosis10.0ESR2, CYP19A1, ESR1
42myoma10.0ESR1, CYP19A1, PGR
43infertility10.0CYP19A1, ESR1, ESR2
44ductal carcinoma in situ10.0ESR1, PGR
45gynecomastia10.0PGR, ESR1, CYP19A1
46tubular adenocarcinoma10.0PGR, ESR1
47chronic lymphocytic leukemia10.0BCL2, BAX, BIRC5
48breast fibroadenoma10.0ESR1, PGR
49factor vii deficiency10.0VEGFA, CYP19A1, ESR1, MUC16
50cervical cancer10.0BCL2, BAX, BIRC5

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to ovarian serous cystadenocarcinoma

Symptoms for Ovarian Serous Cystadenocarcinoma

About this section

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
6CenterWatch, 43NIH Clinical Center, 7ClinicalTrials, 63UMLS, 42NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Ovarian Serous Cystadenocarcinoma

Drug clinical trials:

Search ClinicalTrials for Ovarian Serous Cystadenocarcinoma

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Search CenterWatch for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

About this section

Anatomical Context for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
34MalaCards
See all sources

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

34
Breast, Ovary

Animal Models for Ovarian Serous Cystadenocarcinoma or affiliated genes

About this section
Sources:
38MGI
See all sources

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

38 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.2CYP19A1, BCL2, ESR2, FAS, BAX
2MP:00053759.0CYP19A1, BCL2, AKT1, ESR1, ESR2
3MP:00053718.9ESR2, BAX, FAS, VEGFA, PGR, ESR1
4MP:00053708.9FAS, AKT1, ESR2, VEGFA, CYP19A1, ESR1
5MP:00028738.8BIRC5, AKT1, CYP19A1, VEGFA, PGR, ESR2
6MP:00053888.6BAX, BCL2, AKT1, ESR1, FAS, VEGFA
7MP:00020068.6BCL2, AKT1, FAS, ESR1, ESR2, PGR
8MP:00053678.3BAX, BCL2, VEGFA, FAS, ESR1, ESR2
9MP:00053908.0FAS, ESR1, ESR2, PGR, VEGFA, USP14
10MP:00053697.9ESR2, BCL2, AKT1, ESR1, PGR, VEGFA
11MP:00053977.9BAX, VEGFA, PGR, ESR2, ESR1, FAS
12MP:00053877.9BAX, BIRC5, BCL2, AKT1, FAS, CYP19A1
13MP:00107717.9AKT1, ESR2, BCL2, FAS, ESR1, PGR
14MP:00053807.9BIRC5, VEGFA, PGR, AKT1, ESR1, NANOG
15MP:00036317.8AKT1, CYP19A1, BAX, BCL2, USP14, FAS
16MP:00030127.8VEGFA, ESR1, USP2, PGR, NANOG, ESR2
17MP:00053787.8CYP19A1, VEGFA, BCL2, USP14, FAS, AKT1
18MP:00053857.8CYP19A1, VEGFA, BCL2, AKT1, FAS, ESR1
19MP:00053797.6USP2, ESR2, VEGFA, FAS, AKT1, BCL2
20MP:00053897.1BAX, CYP19A1, USP14, USP2, VEGFA, PGR
21MP:00053867.0CYP19A1, USP14, USP2, PGR, ESR2, ESR1
22MP:00053766.8BCL2, BIRC5, BAX, ESR2, USP14, AKT1
23MP:00107686.8ESR1, BAX, ESR2, FAS, AKT1, USP14
24MP:00053846.6BAX, CYP19A1, VEGFA, BCL2, BIRC5, AKT1

Publications for Ovarian Serous Cystadenocarcinoma

About this section
Sources:
53PubMed
See all sources

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 14)
idTitleAuthorsYear
1
Ovarian serous cystadenocarcinoma metastasising to the breast. (23445161)
2013
2
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. (21266826)
2010
3
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. (18574502)
2008
4
Plasma cell leukemia with ovarian serous cystadenocarcinoma. (17883177)
2007
5
Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. (17553343)
2007
6
ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. (17160949)
2006
7
Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. (16793610)
2006
8
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. (11201519)
2001
9
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. (11516810)
2001
10
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. (10968352)
2000
11
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. (9506768)
1998
12
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. (2314830)
1990
13
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). (3165255)
1988
14
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. (3598277)
1987

Variations for Ovarian Serous Cystadenocarcinoma

About this section

Expression for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
2BioGPS, 16Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
51PathCards, 39NCBI BioSystems Database, 56Reactome, 52PharmGKB, 55R&D Systems, 61Thomson Reuters, 54QIAGEN, 62Tocris Bioscience, 31KEGG, 5Cell Signaling Technology, 58SinoBiological
See all sources

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 58)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9BAX, BCL2
29.9BAX, BCL2
3
Show member pathways
IL-9 Signaling Pathway39
Development Thrombopoietin regulated cell processes61
IL-7 Signaling Pathway39
Immune response IL 9 signaling pathway61
9.8AKT1, BIRC5, BAX
49.8AKT1, BAX, BIRC5
59.7AKT1, ESR2, ESR1
69.7AKT1, ESR2, ESR1
7
Show member pathways
Development Ligand independent activation of ESR1 and ESR261
9.7ESR1, AKT1, ESR2
89.7PGR, CYP19A1, ESR2
9
Show member pathways
IL23-mediated signaling events39
Immune response IL 10 signaling pathway61
Angiopoietin receptor Tie2-mediated signaling39
Development PDGF signaling via STATs and NF kB61
Development Angiopoietin Tie2 signaling61
9.7BCL2, BIRC5, AKT1
109.7BCL2, AKT1, BIRC5
11
Show member pathways
9.7ESR1, ESR2, CYP19A1
12
Show member pathways
9.6BAX, BCL2, AKT1
139.6BAX, AKT1, BCL2
14
Show member pathways
9.6BCL2, BAX, AKT1
15
Show member pathways
9.6BAX, BCL2, AKT1
16
Show member pathways
Apoptosis and survival BAD phosphorylation61
Development Alpha 2 adrenergic receptor activation of ERK61
Chemotaxis CXCR4 signaling pathway61
9.6BCL2, BAX, AKT1
179.6AKT1, BCL2, BAX
18
Show member pathways
Prostate Cancer39
Integrated Cancer pathway39
Steroid Biosynthesis39
9.6AKT1, BCL2, BAX
199.6AKT1, BCL2, BAX
20
Show member pathways
Nuclear Receptors39
9.6PGR, ESR2, ESR1
21
Show member pathways
Cell cycle ESR1 regulation of G1 S transition61
Immune response MIF JAB1 signaling61
Cell cycle Cell cycle generic schema 61
9.6ESR1, PGR, AKT1
229.6BCL2, FAS, BAX
23
Show member pathways
9.6FAS, BCL2, BAX
249.6BCL2, AKT1, ESR1
25
Show member pathways
Development VEGF signaling via VEGFR2 generic cascades61
9.5AKT1, ESR1, VEGFA
269.5BCL2, AKT1, VEGFA
27
Show member pathways
Signal transduction PTEN pathway61
9.4AKT1, BIRC5, BCL2, BAX
289.4BAX, BIRC5, BCL2, AKT1
299.4BAX, FAS, BCL2, BIRC5
30
Show member pathways
Apoptosis and survival Apoptotic TNF family pathways61
9.4FAS, BAX, BIRC5, BCL2
31
Show member pathways
FAS pathway and Stress induction of HSP regulation39
Apoptosis and survival FAS signaling cascades61
Caspase cascade in apoptosis39
9.4BAX, AKT1, FAS, BCL2
32
Show member pathways
9.4FAS, AKT1, BCL2, BAX
33
Show member pathways
Apoptosis and survival TNFR1 signaling pathway61
TWEAK Signaling Pathway39
Apoptosis Modulation by HSP7039
HIV-1 Nef- Negative effector of Fas and TNF-alpha39
9.4BAX, BCL2, FAS, AKT1
34
Show member pathways
9.4BCL2, BAX, AKT1, FAS
359.3BAX, BCL2, ESR2, ESR1
36
Show member pathways
Cytoskeleton remodeling FAK signaling61
Development Endothelin 1 EDNRA transactivation of EGFR61
9.3AKT1, ESR1, ESR2, VEGFA
37
Show member pathways
Apoptosis Modulation and Signaling39
Apoptosis39
9.1BCL2, FAS, AKT1, BIRC5, BAX
38
Show member pathways
Toll-like receptor signaling pathway39
Regulation of toll-like receptor signaling pathway39
9.1BAX, BIRC5, BCL2, FAS, AKT1
39
Show member pathways
9.1BAX, BCL2, AKT1, BIRC5, FAS
40
Show member pathways
9.1ESR2, BIRC5, AKT1, BCL2, ESR1
41
Show member pathways
Prolactin Signaling Pathway39
Development Prolactin receptor signaling61
Leptin signaling pathway39
9.1ESR1, AKT1, BCL2, BAX, ESR2
429.0VEGFA, NANOG, ESR2
43
Show member pathways
Development EGFR signaling via PIP361
Development PDGF signaling via MAPK cascades61
Apoptosis and survival Anti apoptotic action of membrane bound ESR161
Signaling of Hepatocyte Growth Factor Receptor39
Development EGFR signaling via small GTPases61
Development Neurotrophin family signaling61
Apoptosis and survival NGF signaling pathway61
Apoptosis and survival Role of CDK5 in neuronal death and survival61
9.0ESR1, BAX, FAS, AKT1, BCL2
44
Show member pathways
9.0AKT1, VEGFA, BCL2, BAX, FAS
45
Show member pathways
8.9AKT1, ESR1, ESR2, NANOG
46
Show member pathways
DNA damage response (only ATM dependent)39
Wnt Signaling Pathway and Pluripotency39
8.8BAX, NANOG, BCL2, AKT1
478.8BAX, VEGFA, AKT1, FAS, BCL2, BIRC5
488.7BCL2, ESR1, BAX, AKT1, CYP19A1, VEGFA
498.4VEGFA, NANOG, AKT1, FAS, ESR1
508.4BCL2, ESR2, ESR1, FAS, BAX, VEGFA

Compounds for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
46Novoseek, 25HMDB, 52PharmGKB, 12DrugBank, 62Tocris Bioscience, 30IUPHAR, 3BitterDB
See all sources

Compounds related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show top 50)    (show all 235)
idCompoundScoreTop Affiliating Genes
1idoxifene469.7PGR, ESR1, CYP19A1
2estradiol benzoate469.7ESR1, PGR, CYP19A1, ESR2
3nandrolone46 2510.7CYP19A1, PGR, ESR1, ESR2
4leuprolide acetate469.7ESR1, ESR2, PGR, CYP19A1
5anastrozole46 52 1211.6ESR1, PGR, CYP19A1, ESR2
6exemestane46 52 62 1212.6ESR1, CYP19A1, PGR, ESR2
7bisphenol a469.6PGR, CYP19A1, ESR2, ESR1
8lapatinib46 52 1211.6BIRC5, PGR, CYP19A1, ESR1
9clomiphene citrate469.6ESR2, ESR1, PGR, CYP19A1
103,3-diindolylmethane469.6BAX, BIRC5, ESR1, VEGFA
11hoechst 33342469.6BCL2, BIRC5, FAS, BAX
12toremifene46 1210.5CYP19A1, PGR, ESR1, FAS, ESR2
13fulvestrant46 52 30 1212.5ESR1, CYP19A1, PGR, ESR2
144-hydroxytamoxifen469.4CYP19A1, PGR, ESR2, ESR1, AKT1
15letrozole46 52 62 1212.4ESR1, ESR2, PGR, CYP19A1
16indole-3-carbinol469.3CYP19A1, ESR1, AKT1, BIRC5, BCL2, BAX
17gefitinib46 52 1211.2BIRC5, AKT1, ESR1, ESR2, VEGFA, CYP19A1
18adriamycin469.2PGR, FAS, AKT1, BAX, BCL2, BIRC5
19celecoxib46 62 30 52 25 1214.2BCL2, AKT1, VEGFA, CYP19A1, BIRC5, BAX
20progestin469.2PGR, VEGFA, ESR2, ESR1, CYP19A1
21gemcitabine46 52 1211.2BAX, BCL2, AKT1, VEGFA, CYP19A1, BIRC5
22thymidylate469.1FAS, ESR2, BIRC5, BAX, VEGFA, BCL2
23trastuzumab46 52 1211.1CYP19A1, VEGFA, PGR, ESR1, FAS, BIRC5
24egcg469.1BAX, VEGFA, ESR2, FAS, BCL2, BIRC5
25taxane469.1ESR1, BCL2, PGR, CYP19A1, VEGFA, BIRC5
26levonorgestrel46 62 30 1212.1ESR1, PGR, CYP19A1, ESR2
27etoposide46 52 62 1212.0BAX, BIRC5, BCL2, FAS, ESR2, AKT1
28mifepristone46 30 62 1211.9CYP19A1, VEGFA, PGR, ESR2, ESR1, BAX
29arsenite46 259.9AKT1, VEGFA, FAS, PGR, BAX, BIRC5
30mg 13246 629.9BIRC5, BCL2, BAX, VEGFA, AKT1, FAS
31docetaxel46 52 62 1211.8CYP19A1, BAX, PGR, BIRC5, BCL2, ESR1
32ly294002468.8ESR1, FAS, AKT1, VEGFA, BCL2, BIRC5
33sb 20358046 629.8BAX, BCL2, AKT1, FAS, VEGFA, BIRC5
34cyclophosphamide46 52 1210.7BCL2, MUC16, ESR1, PGR, VEGFA, CYP19A1
35n acetylcysteine468.7FAS, VEGFA, AKT1, BAX, BCL2, BIRC5
36actinomycin d468.6BCL2, BIRC5, BAX, ESR1, VEGFA, ESR2
37resveratrol46 62 25 1211.6VEGFA, PGR, ESR2, ESR1, FAS, BCL2
385fluorouracil468.5BCL2, BAX, BIRC5, CYP19A1, ESR1, FAS
39testosterone46 62 25 1211.5FAS, MUC16, AKT1, BIRC5, ESR1, ESR2
40cisplatin46 52 62 1211.4MUC16, FAS, AKT1, BCL2, ESR1, BIRC5
41retinoic acid46 259.4BIRC5, BAX, BCL2, AKT1, FAS, ESR2
42dexamethasone46 52 30 1211.1ESR2, VEGFA, CYP19A1, PGR, FAS, AKT1
43genistein46 30 62 3 25 1213.1AKT1, FAS, ESR1, ESR2, PGR, VEGFA
44tamoxifen46 52 30 1211.1PGR, VEGFA, CYP19A1, ESR2, ESR1, BAX
45cycloheximide468.1BIRC5, BAX, AKT1, BCL2, PGR, FAS
46paraffin467.9BAX, BIRC5, BCL2, AKT1, FAS, MUC16
47vegf467.9VEGFA, AKT1, PGR, BCL2, MUC16, ESR1
48estrogen467.9VEGFA, CYP19A1, MUC16, ESR2, PGR, ESR1
49paclitaxel46 52 129.9MUC16, BAX, BIRC5, BCL2, AKT1, FAS
50doxorubicin46 52 129.6CYP19A1, BAX, ESR2, BIRC5, BCL2, FAS

GO Terms for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
Sources:
17Gene Ontology
See all sources

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1pore complexGO:0469309.8BAX, BCL2
2mitochondrial outer membraneGO:0057419.3PGR, BCL2, BAX
3nucleoplasmGO:0056548.2AKT1, PGR, NANOG, ESR2, ESR1, ZNF217
4nucleusGO:0056347.1USP2, BIRC5, BCL2, AKT1, FAS, ESR1

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 43)
idNameGO IDScoreTop Affiliating Genes
1activation-induced cell death of T cellsGO:00692410.4AKT1, FAS
2transformed cell apoptotic processGO:00692710.3FAS, BAX
3regulation of nitrogen utilizationGO:00680810.3BAX, BCL2
4uterus developmentGO:06006510.3ESR2, ESR1
5regulation of protein heterodimerization activityGO:04349710.3BCL2, BAX
6positive regulation of extrinsic apoptotic signaling pathway in absence of ligandGO:200124110.3BAX, FAS
7regulation of protein homodimerization activityGO:04349610.3BCL2, BAX
8endoplasmic reticulum calcium ion homeostasisGO:03246910.3BCL2, BAX
9positive regulation of nitric-oxide synthase activityGO:05100010.3ESR1, AKT1
10response to acidGO:00110110.2BAX, BCL2
11renal system processGO:00301410.2FAS, BCL2
12negative regulation of autophagyGO:01050710.2AKT1, BCL2
13negative regulation of apoptotic signaling pathwayGO:200123410.2BCL2, BAX
14androgen metabolic processGO:00820910.2CYP19A1, ESR1
15cellular response to organic substanceGO:07131010.2BCL2, BAX
16intracellular estrogen receptor signaling pathwayGO:03052010.2ESR1, ESR2
17apoptotic mitochondrial changesGO:00863710.2BAX, AKT1
18B cell homeostasisGO:00178210.1BCL2, BAX
19positive regulation of blood vessel endothelial cell migrationGO:04353610.1VEGFA, AKT1
20mammary gland alveolus developmentGO:06074910.1VEGFA, ESR1
21vagina developmentGO:06006810.1ESR2, ESR1, BAX
22regulation of mitochondrial membrane potentialGO:05188110.1BAX, BCL2
23intrinsic apoptotic signaling pathwayGO:09719310.0AKT1, BCL2, BAX
24negative regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:04315410.0BIRC5, AKT1, VEGFA
25positive regulation of sequence-specific DNA binding transcription factor activityGO:05109110.0AKT1, ESR1, ESR2
26homeostasis of number of cells within a tissueGO:04887310.0BAX, BCL2
27extrinsic apoptotic signaling pathway via death domain receptorsGO:00862510.0FAS, BCL2, BAX
28extrinsic apoptotic signaling pathway in absence of ligandGO:09719210.0BAX, BCL2, FAS
29intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressGO:07005910.0BCL2, BAX
30response to toxic substanceGO:00963610.0BAX, BCL2, FAS
31release of cytochrome c from mitochondriaGO:0018369.9BAX, BCL2
32positive regulation of peptidyl-serine phosphorylationGO:0331389.9BCL2, AKT1, VEGFA
33cellular response to hypoxiaGO:0714569.9BCL2, AKT1, VEGFA
34response to gamma radiationGO:0103329.9BAX, BCL2
35ovarian follicle developmentGO:0015419.7BAX, BCL2, ESR2, VEGFA
36transcription initiation from RNA polymerase II promoterGO:0063679.6ESR1, ESR2, PGR
37positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathwayGO:19007409.6BCL2, AKT1
38apoptotic processGO:0069159.5FAS, AKT1, BCL2, BIRC5, BAX
39negative regulation of apoptotic processGO:0430669.4VEGFA, FAS, AKT1, BCL2, BIRC5
40signal transductionGO:0071659.4PGR, ESR2, ESR1, FAS, AKT1
41positive regulation of mitotic cell cycleGO:0459319.2BIRC5, NANOG, USP2
42ubiquitin-dependent protein catabolic processGO:0065119.0USP14, USP2, UBE4A
43negative regulation of transcription from RNA polymerase II promoterGO:0001228.3USP2, VEGFA, NANOG, ESR2

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards/GeneDecks:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1estrogen response element bindingGO:03405610.1ESR1, ESR2
2estrogen receptor activityGO:03028410.0ESR2, ESR1
3BH3 domain bindingGO:05143410.0BAX, BCL2
4core promoter sequence-specific DNA bindingGO:0010469.9ESR1, ESR2
5nitric-oxide synthase regulator activityGO:0302359.9AKT1, ESR1
6steroid bindingGO:0054969.8ESR1, ESR2, PGR
7steroid hormone receptor activityGO:0037079.8PGR, ESR2, ESR1
8channel activityGO:0152679.8BAX, BCL2
9enzyme bindingGO:0198999.4PGR, ESR2, ESR1, AKT1, BIRC5
10protein heterodimerization activityGO:0469829.0VEGFA, BCL2, BIRC5, BAX
11identical protein bindingGO:0428028.1BAX, USP2, VEGFA, ESR1, FAS, AKT1
12protein bindingGO:0055155.6ESR1, ESR2, PGR, VEGFA, USP2, USP14

Products for genes affiliated with Ovarian Serous Cystadenocarcinoma

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Ovarian Serous Cystadenocarcinoma

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
30IUPHAR
31KEGG
36MeSH
37MESH via Orphanet
38MGI
41NCIt
42NDF-RT
45NINDS
46Novoseek
48OMIM
49OMIM via Orphanet
53PubMed
54QIAGEN
60SNOMED-CT via Orphanet
63UMLS
64UMLS via Orphanet